From MarketBeat:

Cresco Labs Inc. saw a significant drop in short interest in December, with a decrease of 19.5% from the previous total. As of December 31st, there was short interest totaling 1,282,700 shares, resulting in an average ratio of 0.8 days.

Wall Street analysts have reissued an “outperform” rating on Cresco Labs shares, with three analysts giving the stock a hold rating and two rating it a buy. The average target price for the stock is $6.58.

Cresco Labs’ stock traded up $0.26 during mid-day trading on Monday, reaching $1.93 per share. The company’s market capitalization stands at $667.05 million, with a PE ratio of -1.77. The current fiscal year is expected to see Cresco Labs post -0.41 earnings per share.

Cresco Labs last released its earnings results on November 15th, reporting ($0.04) earnings per share for the quarter and a revenue of $190.56 million. Research analysts expect that Cresco Labs will post a negative return on equity of -11.72% for the current fiscal year.

Cresco Labs Inc. cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in various forms under different brand names, offering a range of products to its customers. Overall, the company has a negative net margin of 43.40%.



Read more: Cresco Labs Inc. (OTCMKTS:CRLBF) Short Interest Update